Brokerages Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Price Target at $22.17

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has been given an average rating of “Buy” by the seven analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $22.17.

Several research analysts recently weighed in on the company. Guggenheim reiterated a “buy” rating on shares of Phathom Pharmaceuticals in a research report on Wednesday, April 2nd. HC Wainwright reaffirmed a “buy” rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Friday, March 7th. The Goldman Sachs Group lowered their price target on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a “neutral” rating on the stock in a report on Monday, March 10th. Craig Hallum reaffirmed a “buy” rating on shares of Phathom Pharmaceuticals in a report on Friday, March 7th. Finally, Cantor Fitzgerald raised shares of Phathom Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, February 25th.

Phathom Pharmaceuticals Stock Performance

Shares of PHAT opened at $4.11 on Friday. The business’s 50-day moving average is $5.47 and its two-hundred day moving average is $9.16. The company has a market capitalization of $286.21 million, a P/E ratio of -0.72 and a beta of 0.35. Phathom Pharmaceuticals has a fifty-two week low of $3.81 and a fifty-two week high of $19.71.

Insider Activity

In related news, insider Terrie Curran sold 19,109 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total value of $125,928.31. Following the transaction, the insider now directly owns 360,465 shares of the company’s stock, valued at approximately $2,375,464.35. This trade represents a 5.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Azmi Nabulsi sold 7,886 shares of Phathom Pharmaceuticals stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $51,968.74. Following the completion of the sale, the chief operating officer now owns 233,390 shares in the company, valued at approximately $1,538,040.10. The trade was a 3.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,256 shares of company stock worth $238,014 over the last 90 days. 24.10% of the stock is currently owned by company insiders.

Institutional Trading of Phathom Pharmaceuticals

Several large investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in Phathom Pharmaceuticals by 797.2% in the 1st quarter. GAMMA Investing LLC now owns 4,558 shares of the company’s stock valued at $29,000 after purchasing an additional 4,050 shares in the last quarter. Kera Capital Partners Inc. lifted its stake in shares of Phathom Pharmaceuticals by 11.2% in the first quarter. Kera Capital Partners Inc. now owns 29,849 shares of the company’s stock worth $187,000 after buying an additional 3,000 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Phathom Pharmaceuticals by 20.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 117,803 shares of the company’s stock worth $957,000 after acquiring an additional 19,778 shares during the last quarter. Two Sigma Advisers LP purchased a new stake in Phathom Pharmaceuticals during the 4th quarter valued at about $1,086,000. Finally, Two Sigma Investments LP raised its holdings in Phathom Pharmaceuticals by 215.4% in the 4th quarter. Two Sigma Investments LP now owns 485,790 shares of the company’s stock valued at $3,945,000 after acquiring an additional 331,760 shares during the last quarter. 99.01% of the stock is currently owned by hedge funds and other institutional investors.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.